

MicroPhage MRSA/MSSA Skin and Soft Tissue Infection Test

Infections of the skin, surgical sites, and wounds are a major concern for clinicians, and identifying the cause of the infection is necessary to effectively prescribe treatment. With 50-percent methicillin resistance in *S. aureus*, understanding how to effectively treat infections is difficult at the clinical level.

Today, no means exist to cost-effectively and rapidly identify the presence of methicillin resistant *S. aureus* (MRSA) and methicillin susceptible *S. aureus* (MSSA). MicroPhage will have the first product to rapidly differentiate these strains in skin and wound infections through our easy-to-use bacteriophage amplification platform – without needing to invest in molecular tests or wait on traditional microbiology.

Improve treatment outcomes for wound and skin infections

The MicroPhage MRSA/MSSA Skin and Soft Tissue Infection Test is designed to rapidly identify the presence of *S. aureus* and determines methicillin susceptibility (MSSA) or methicillin resistance (MRSA). By receiving results days before traditional ID/AST results are available, physicians can effectively prescribe treatment.



- » **Get definitive results faster than standard diagnostic methods** – Receive culture-quality results in hours, not days.
- » **Benefit from an easy-to-use platform** – Go direct from a sample – without the need for expensive equipment, batching, or specialized personnel.
- » **Enable more effective treatments** – Get critical identification and antibiotic susceptibility and resistance information to enable the most-appropriate treatment.
- » **Improve outcomes** – Reduce treatment delays, complications, and costs.
- » **Simplify testing with a phenotypic test** – Rely on viable bacteria for results that are directly related to the sample – no primers or molecular markers.

Availability: Early 2011

This test is not cleared by the U.S. FDA nor CE Marked and not yet available for sale.

www.microphage.com
303.652.5200